-
If you purchased shares of Cubist Pharmaceuticals Inc (NASDAQ:CBST) and currently hold any of those NASDAQ:CBST shares, you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
December 12, 2014 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Cubist Pharmaceuticals Inc (NASDAQ:CBST), was announced concerning whether the takeover of Cubist Pharmaceuticals Inc by Merck for $102 per share is unfair to NASDAQ:CBST stockholders.
The investigation by a law firm concerns whether certain officers and directors of Cubist Pharmaceuticals Inc breached their fiduciary duties owed to NASDAQ:CBST investors in connection with the proposed acquisition.
On December 8, 2014, Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced that the companies have entered into an agreement under which Merck will acquire Cubist for $102 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ:CBST stockholders. More specifically, the investigation concerns whether the Cubist Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Cubist Pharmaceuticals Inc reported that its annual Total Revenue rose from $636.46 million in 2010 to over $1.05 billion in 2013. Shares of Cubist Pharmaceuticals Inc (NASDAQ:CBST) grew from under $20 in early 2010 to as high as $79.59 per share in February 2014.
